Evolving Technologies, Followed By Increasing Awareness &Acceptance of the Adapted Medicineto Drive the Molecular Diagnostic Market: Ken Research REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit Molecular diagnostics detect and measure theexistence of genetic material or proteinsassociated with a specific health conditionor disease to uncover theunderlying mechanisms of disease andenabling clinicians to tailor care at an individual level. These tests are useful in various medical special areas including infectious disease, human leucocyte antigen typing, oncology, coagulation, and pharmacogenomics. According to study, “Worldwide Molecular Diagnostics Market Trends and Drivers, Restraints, and Opportunities 2017-2023” some of the major companies that are currently working in the worldwide molecular diagnostics market areHologic, Inc, F. Hoffmann-la Roche, Danaher Corporation, Siemens Healthineers Inc., Qiagen N.V., Abbott Laboratories, Becton Dickenson and Company, Quest Diagnostics Inc., Abbott Molecular, Tecan Group Ltd., Hoffmann-La Roche Ltd., Illumina, Inc., Diasorin, Grifols International S.A, Advanced Cell Diagnostics, The ELI TechGroup, Roche Diagnostics, Siemens Healthineers Inc., Hologic Corporation, Agilent Technologies/Dako, Amoy Diagnostics, Meridian Bioscience, Biocartis, Genmark Diagnostics, Beijing Genomics Institute (BGI), Myriad Genetics, Bio-ad Laboratories Inc, Exosome Diagnostics, Nanostring Technologies, Applied Spectral Imaging, Laboratory Corporation of America, Orchid Biosciences and Dianon Cellmark Forensics, American Association of Blood Banks, Ariosa Diagnostics, Chronix Biomedical, PerkinElmer, Inc. (PE), Signature Diagnostics, Central Drugs Standard Control Organization, Great Basin Scientific, Genomic Health Inc., Cepheid Inc., Thermo Fisher Scientific, bioMerieux S.A. Based on the technology, the worldwide molecular diagnostic market is segmented into chips & microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT), Transcription Mediated Amplification (TMA), Fluorescence In-Situ hybridization, molecular imaging, cytogenetics, gene expression-based studies, Polymerase Chain Reaction (PCR) based methods, mass spectroscopy and DNA sequencing. Hybridization is further sub-segmented into In-Situ Hybridization (ISH) and Fluorescence In-Situ Hybridization (FISH). Molecular imaging is sub-segmented into FDG-PET and optical imaging. PCR based methods include Cold-PCR, directlinear analysis, real-time PCR, digital-PCR, reverse transcriptase PCR and quantitative fluorescent PCR. DNA sequencing includes Next Generation Sequencing (NGS) and Capillary Electrophoresis (CE). Some of the major advantages of the molecular diagnostic techniques includesensitive & specific, ease of testing, and rapid turnaround time (TAT) and large volume testing. Based on the application, the market is segmented into oncology, human leukocyte antigen typing,infectious disease, pharmacogenomics, blood screening, genetic disease screening and microbiology. Infectious disease includes human immunodeficiency virus (HIV), meningitis, flu, tuberculosis, Chlamydia Trachomatis or Neisseria gonorrhoeae CT/NG, Human papilloma virus (HPV), TB, H.Pylori, dengue, influenza, TORCH and hepatitis. The market of molecular diagnostics is mainly driven by large outbreaks of bacterial & viral epidemics followed by evolving technologies, pharmacogenomics, increasing awareness & acceptance of adapted medicine & companion diagnostics, higher expenditure in life science, increasing patient with bone disorders, increasing government support, concentration of major companies, high prevalence of infectious diseases & different types of cancers, and increasing demand for the point- of-care diagnostics. However, market is also impactedby the restraints such ashigh complexity testing centers, lack of proper reimbursement policies, complex regulatory frameworks, economic turndown and limited budget. Additionally, some new prospects include growth opportunities in emerging markets and advances in genomics & proteomics. America leads the global market for molecular diagnostics owing to growing demand for the advanced techniques & molecular diagnostics. It is estimated that the molecular diagnostics market to reach at US $11.5 billion by 2023 from US$7.1 billion in 2017, at a CAGR of 8.4%. For more information, click on the link below: https://www.kenresearch.com/healthcare/diagnostics/world-wide-molecular/173341-91.html Contact Us: Ken Research Ankur Gupta, Head Marketing & Communications sales@kenresearch.com +91 9015378249 Post Views: 3 Tags: Global Molecular Diagnostics Market, Global Molecular Diagnostics Market Revenue, Worldwide Molecular Diagnostics Business Strategy, Worldwide Molecular Diagnostics Industry Outlook, Worldwide Molecular Diagnostics Industry Overview, Worldwide Molecular Diagnostics Market Drivers, Worldwide Molecular Diagnostics Market Dynamics, Worldwide Molecular Diagnostics Market Forecast, Worldwide Molecular Diagnostics Market Opportunities, Worldwide Molecular Diagnostics Market Research Report, Worldwide Molecular Diagnostics Market Restraints, Worldwide Molecular Diagnostics Market Segmentation, Worldwide Molecular Diagnostics Market Share, Worldwide Molecular Diagnostics Market Trends, Worldwide Molecular Diagnostics SWOT Analysis